NutriBand Inc.

Nutriband Inc. is a U.S.-based pharmaceutical development and services company focused on transdermal drug-delivery products and abuse-deterrent patch technology. Through its subsidiaries, it also provides contract manufacturing and contract research and development services for health, wellness, pharmaceutical, and medical device customers.

−398,9 %

27,8 %

−404,1 %

−4,8 %

6.36

6.21

— NutriBand Inc.
%
AVERSA transdermal products10% Development of abuse-deterrent patch-based drug delivery products using AVERSA technology.
Contract manufacturing70% Manufacturing services for health, wellness, OTC, topical, and transdermal products.
Contract R&D services20% Research and development services for pharmaceutical and medical device customers.

Nutriband sells services to health and wellness, over-the-counter, pharmaceutical, and medical device customers, while...

  • Health and wellness / OTC customersprimary

    Buy contract manufacturing for transdermal, topical, and tape products.

  • Pharmaceutical customersprimary

    Use contract manufacturing and AVERSA-related development for drug patches.

  • Medical device customerssecondary

    Buy contract R&D services related to product development and testing.

  • Drug-delivery partnersprimary

    Collaborate on AVERSA-based transdermal products and clinical supply work.

Nutriband is headquartered in Orlando, Florida, and its manufacturing operations are centered in Cherryville, North...

  • •Headquartered in Orlando, Florida
  • •Manufacturing facility in Cherryville, North Carolina
  • •Most revenue is generated in the United States
  • •European investors participated in a private financing
  • •U.S. regulatory exposure is central to product development

Nutriband's strategy centers on advancing AVERSA-based transdermal products through development and regulatory...

01
Advance AVERSA lead product developmentmedium-term

The platform is the core proprietary asset and the main long-term value driver.

02
Expand contract manufacturing utilizationshort-term

Manufacturing services provide operating revenue and support facility economics.

03
Maintain external development partnershipsmedium-term

Shared-cost collaborations reduce funding burden and add technical capability.

Nutriband faces development, regulatory, and funding risk because its lead products depend on FDA approval and...

high

FDA and regulatory approval risk

Transdermal drug products must clear lengthy regulatory review before commercialization.

Scope
Lead AVERSA product pipeline
Materiality
high
high

Product safety and liability risk

Unexpected adverse events or misuse concerns could trigger recalls or enforcement.

Scope
Transdermal pharmaceutical products
Materiality
high
high

Financing and liquidity risk

Development-stage companies often need external capital to fund R&D and operations.

Scope
Corporate funding and product development
Materiality
high
medium

Customer concentration and program dependence

Contract manufacturing and R&D revenue can be tied to a limited set of customers.

Scope
Pocono Pharmaceuticals and 4P Therapeutics
Materiality
medium
Revenue recognition under contracts with customers
Product sales are point-in-time; R&D services are recognized over time
Deferred revenue
Can shift revenue between periods
Going concern and liquidity estimates
Affects disclosure, investor perception, and capital structure analysis
Lease accounting
Impacts leverage and fixed-obligation analysis
R&D expense recognition
Suppresses near-term earnings while supporting pipeline investment

Minerva Neurosciences, Inc.

NERV · Pharmaceutical Preparations

PULSE BIOSCIENCES, INC.

PLSE · Surgical & Medical Instruments & Apparatus

Nu-Med Plus, Inc.

NUMD · Surgical & Medical Instruments & Apparatus

Lifevantage Corp

LFVN · Pharmaceutical Preparations

Entera Bio Ltd.

ENTX · Biological Products, (No Diagnostic Substances)

ORAMED PHARMACEUTICALS INC.

ORMP · Pharmaceutical Preparations

: 29/04/2026